First-in-Class Therapies Designed to Reprogram the Immune System


COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR’s lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions.

COUR Nanoparticle Platform: CNP

  • Reprograms the immune system
  • Induces tolerance to specific antigens
  • Preserves all immune functionality

Inducing Immune Tolerance in Autoimmune & Allergic Diseases

Rapidly Advancing First-in-Class Therapies for Immune-Mediated Diseases

CNP-101/TAK-101 (Celiac Disease) CNP-201 (Peanut Allergy) CNP-104 (Primary Biliary Cholangitis) CNP-T1D (Type 1 Diabetes) CNP-MYG (Myasthenia Gravis) CNP-ITP (Immune Thrombocytopenia Purpura) View Full